IDEXX Laboratories, Inc. $IDXX Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 57.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 225 shares of the company’s stock after purchasing an additional 82 shares during the quarter. TD Private Client Wealth LLC’s holdings in IDEXX Laboratories were worth $121,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after acquiring an additional 825,965 shares during the period. Select Equity Group L.P. purchased a new stake in shares of IDEXX Laboratories during the 1st quarter worth $194,834,000. Nuveen LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter worth $179,784,000. Principal Financial Group Inc. boosted its position in shares of IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock worth $472,865,000 after purchasing an additional 414,802 shares in the last quarter. Finally, Durable Capital Partners LP purchased a new stake in shares of IDEXX Laboratories during the 1st quarter worth $153,180,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on IDXX shares. Piper Sandler restated a “neutral” rating and set a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 4th. Leerink Partners boosted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $649.44.

IDEXX Laboratories Stock Down 0.3%

IDXX opened at $630.56 on Tuesday. The firm has a 50 day moving average price of $627.80 and a 200 day moving average price of $530.50. The company has a market cap of $50.45 billion, a PE ratio of 52.50, a price-to-earnings-growth ratio of 4.09 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other news, EVP Sharon E. Underberg sold 5,450 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. This represents a 46.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock worth $34,293,468 over the last 90 days. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.